Louis Saravolatz, MD
Infectious Disease · Grosse Pointe Woods, MINPI 1891788865
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 61.9% of it on its own, with 3 other manufacturers making up the rest.
Across 17 payments — averaging $165.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Pfizer$930
- Boston Scientific$85
- Janssen Products, LP$55
Across 269 payments — averaging $9823.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.2M
- GSK$253K
- Merck$144K
- Melinta Therapeutics, LLC$18K
What the payments were for
- Consulting fees$93033%
- Travel & lodging$1,23844%
- Food & beverage$58721%
- Education$552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $1,739 |
| Pfizer | 1 | $930 |
| Boston Scientific | 1 | $85 |
| Janssen Products, LP | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LAGEVRIO$1,335
How this compares
$2,809 in reported general payments places this provider in the 85th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $130,204 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $77,045 |
| TivicayDolutegravir Sodium | 14 | $32,063 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $31,280 |
| Rosuvastatin Calcium | 13 | $363 |
| Amlodipine Besylate | 11 | $108 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Grosse Pointe Woods
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Christopher CarpenterRoyal Oak$27K
- Marcus ZervosDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.